We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ADMA Biologics, Inc. is one of the best ...

ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best low priced biotech stocks to invest in. Mizuho cut the price target on ...

Fintel reports that on April 21, 2026, Canaccord Genuity initiated coverage of ADMA Biologics (NasdaqGM:ADMA) with a Buy recommendation. Analyst Price Forecast Suggests 122.15% Upside As of April 15, ...

The MarketWatch News Department was not involved in the creation of this content. Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ADMA BIOLOGICS, INC. (ADMA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) saw the price of their shares slide over 16% on March 24, 2026 on short seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income (1) of ...

BFA Law is investigating ADMA Biologics after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK--(BUSINESS WIRE)--$ADMA ...

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ...

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and ...